|
Zangani Investor Community Announces Interview with Biophan Technologies, Inc. President Michael Weiner
Interview Available on Zangani Website and Via Podcast
 Print View
April 4, 2006 (FPRC) -- Zangani Investor Community, an outsourced IR and Business Development firm announced today that they interviewed Michael Weiner, President and CEO of Biophan Technologies, Inc., on April 3rd, 2006. Mr. Riedlinger discussed the latest business opportunities for the company including its recent announcement that it intends to enter into negotiations for a strategic collaboration with Siemens Medical Solutions MRI Division in Europe.
To access the interview, please visit the Zangani Investor Community at:
www.zangani.com/biophan/2006-0403-biph. The interview is also available via Podcast at www.zangani.com or through the itunes music store.
About Biophan Technologies, Inc.
Biophan develops and markets cutting-edge technologies for the medical device industry that provide competitive advantages. The Company's founding goal was to make all biomedical devices capable of safely and successfully working with magnetic resonance imaging (MRI), problems which the Company has solved and begun to license to leading device manufacturers. The Company's mission has expanded to provide other technologies which will improve the delivery of healthcare. Biophan's technologies enable medical systems such as pacemakers, interventional surgical devices such as catheters and guidewires, and implants such as stents to be safely and/or effectively imaged under MRI. The Company is helping to commercialize the MYO-VAD(TM), a novel, MRI-compatible ventricular assist device which has significant potential to improve the treatment of many forms of acute and chronic heart disease. Other applications in development include drug delivery and power systems which derive energy from body heat. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 156 U.S. patents, licenses, or applications, plus international applications. This total includes 50 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 98 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), medical device designs, radio frequency filters, polymer composites, thermoelectric materials, and photonics. Biophan has joint development and licensing agreements with Boston Scientific Corporation and NASA's Ames Center for Nanotechnology. Biophan is traded on the OTC market under the symbol BIPH, and is also listed on the Frankfurt Stock Exchange under the symbol BTN.
About Zangani
Zangani is an outsourced IR and Business Development firm specializing in small cap and micro cap companies. They provide clients with an array of investor relations products, including customized company strategies, community forums, and webcasting which are tailored for small cap budgets. For more information please visit their website at http://www.zangani.com
Note: Except for the historical information contained herein, this press release contains, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Such statement may include, without limitation, statements with respect to the Company’s plans, objectives, expectations and intentions and other statements identified by words such as “may”, “could”, “would”, “should”, “believes”, “expects”, “anticipates”, “estimates”, “intends”, “plans” or similar expressions. These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control).
L.G. Zangani, LLC provides financial public relations service to the Company. As such L.G. Zangani, LLC and/or its officers, agents and employees, receives remuneration for public relations and or other services in the form of monies, capital stock in the Company, warrants or options to purchase capital in the Company. The full disclaimer can be read here at http://www.zangani.com/disclaimer.
Contact:
Kevin Nally
Zangani Investor Community
9 Main Street
Flemington, NJ 08822
office@zangani.com
http://www.zangani.com
Send an email to Kevin Nally of Zangani
908-788-9660
Keywords:
Biophan, Zangani, webcast
|
